PROBIOTICS IN THE TREATMENT OF INFLAMMATORY BOWEL DISEASES IN CHILDREN


如何引用文章

全文:

详细

The development of inflammatory bowel disease (IBD): Crohn's disease (CD) and ulcerative colitis (UC) are due to violation of the interaction of the intestinal microbiota and the immune system of the intestine. Taking account of favorable effect of probiotics on the protective intestinal barrier and formation of immunological tolerance, they can be used in the treatment of IBD. Only a few studies were aimed to this problem in children. The purpose of this study was evaluation of effectiveness of Saccharomyces boulardii (Enterol) in remission maintenance in 24 children with BC, who were randomized into 2 groups of 12 persons after remission induction. In the first group, Mesalazine at a dose of 50 mg/kg was used as maintenance therapy and in the second group in the first 3 months Enterol at a dose of 500 mg/day of treatment was used in addition to Mesalazine. The dynamics of clinical picture and calprotectin level in feces were assessed before treatment and after 6 months. Exacerbation occurred in 8.3% of children receiving Enterol, and in 25% - not receiving Enterol. Calprotectin level in feces was significantly decreased in the group receiving Enterol.

参考

  1. Swidsinski A, Ladhoff A, Pemthaler A, et al. Mucosal flora in inflammatory bowel disease. Gastroenterology 2002;122:44-54.
  2. Kuhn R, Lohler J, Rennick D, et al. Interleukin-10-deficient mice develop chronic enterocolitis. Cell 1993;75:263-74.
  3. Gionchetti P, Rizzello F, Venturi A, et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a doubleblind, placebo-controlled trial. Gastroenterology 2000; 119:305-309.
  4. Mimura T, Rizzello F, Helwig U, et al. Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut 2004;53:108-14.
  5. Kuisma J, Mentula S, Jarvinen H, et al. Effect of Lactobacillus rhamnosus GG on ileal pouch inflammation and microbial flora.Aliment Pharmacol Ther 2003;17:509-15.
  6. Laake KO, Line PD, Aabakken L, et al. Assessment of mucosal inflammation and circulation in response to probiotics in patients operated with ileal pouch anal anastomosis for ulcerative colitis. Scand J Gastroenterol 2003;38:409-14.
  7. Gionchetti P, Rizzello F, Helwig U, et al. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology 2003;124:1202-09.
  8. Bibiloni R, Fedorak RN, Tannock GW, et al. VSL#3 probioticmixture induces remission in patients with active ulcerative colitis. Am J Gastroenterol 2005;100:1539-46.
  9. Rembacken BJ, Snelling AM, Hawkey PM, et al. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet 999;354:635-39.
  10. Rioux KP, Fedorak RN. Probiotics in the treatment of inflammatory bowel disease. J Clin Gastroenterol 2006;40:260-63.
  11. Guslandi M, Giollo P, Testoni PA. A pilot trial of Saccharomyces boulardii in ulcerative colitis. Eur J Gastroenterol Hepatol 2003;15:697-98.
  12. Kruis W, Schutz E, Fric P, et al. Double-blind comparison of an oral Escherichia coli reparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 1997;11:853-58.
  13. Kruis W, Fric P, Pokrotnieks J, et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 2004;53:1617-23.
  14. Ishikawa H, Akedo I, Umesaki Y, et al. Randomized controlled trial of the effect of bifidobacteria-fermented milk on ulcerative colitis. J Am Coll Nutr 2003;22:56-63.
  15. Venturi A, Gionchetti P, Rizzello F, et al. Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis.Aliment Pharmacol Ther 1999;13:1103-08.
  16. Gupta P, Andrew H, Kirschner BS, et al. Is Lactobacillus GG helpful in children with Crohn's disease? Results of preliminary, open-label study. J Pediatr Gastroenterol Nutr 2000; 31:453-57.
  17. Schultz M, Timmer A, Herfarth HH, et al. Lactobacillus GG in inducing and maintaining remission of Crohn's disease. BMC Gasroenterol 2004;4:5.
  18. Bousvaros A, Guandalini S, Baldassano RN, et al. A ranomized, double-blind trial of Lactobacillus GG versus placebo in addition to standard maintenance therapy for children with Crohn's disease. Inflamm Bowel Dis 2005;11:833-39.
  19. Prantera C, Scribano ML, Falasco G, et al. Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: a randomised controlled trial with Lactobacillus GG. Gut 2002;51:405-09.
  20. Plein K, Hotz J. Therapeutic effects of Saccharamyces boulardii on mild residual symptoms in stable phase of Crohn's disease with special respect to chronic diarrhea - a pilot study. J Gasroenterol 1993;31:129-34.
  21. Guslandi M, Mezzi G, Sorghi M, et al. Saccharomyces boulardii in maintenance treatment of Crohn's disease. Dig Dis Sci 2000;45:1462-64.
  22. Czerucka D, Dahan S, Mograbi B, et al. Saccharomyces boulardii preserves the barrier function and modulates the signal transduction pathway induced in enteropathogenic Escherichia coli-infected T84 cells. Infect Immun 2000; 68:5998-6004.
  23. Dahan S, Dalmasso G, Imbert V, et al. Saccharomyces boulardii interferes with enterohemorragic Escherichia coli-induced signaling pathways in T84 cells. Infect Immun 2003;71:766-73.
  24. Czerucka D, Dahan S, Mograbi B, et al. Implication of mitogen-activated protein kinases in T84 cell responses to enteropathogenic Escherichia coli infection. Infect Immun 2001;69:1298-1305.
  25. Resta-Lenert S, Barrett KE. Live probiotics protect intestinal epithelial cells from the effects of infection with enteroinvasive Escherichia coli (EIEC). Gut 2003;52:988-97.
  26. Ruemmelle FM, Bier D, Marteau P, et al. Clinical evidence of immunomodulatory effects of probiotic bacteria. J Pediatr Gastroenterol Nutr 2009; 48(2):126-41.
  27. Foligne B, Zoumpopoulou G, Dewulf J, et al. A key role of dendritic cells in probiotic functionality. PLoS ONE 2007;2:313.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2010
##common.cookie##